患有心力衰竭的患者中脂质参数的预后值:系统性审查和元分析
Ahmed Sayed1, Hesham Afify2, Malak Munir1
1Faculty of Medicine, Ain Shams University, Cairo, Egypt.
ESC heart failure
|May 24, 2025
概括
较高的脂质水平,包括总胆固醇和LDL胆固醇,与心力衰竭 (HF) 患者的死亡率降低有关. 这些脂质参数可能有助于预测HF患者的结果.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生化学
- 流行病学 流行病学
背景情况:
- 心力衰竭 (HF) 是一种复杂的临床综合征,具有显著的死亡率.
- 在HF患者中脂质参数的预后作用仍然不完全理解.
- 准确的预后对于指导HF的临床管理和治疗策略至关重要.
研究的目的:
- 在被诊断为心力衰竭的患者中系统评估关键脂质参数的预后意义.
- 评估总胆固醇 (TC),高血压胆固醇,低血压胆固醇和甘油三与高血压胆固醇死亡风险之间的关联.
主要方法:
- 在主要的电子数据库 (MEDLINE,Embase,CENTRAL,Web of Science) 进行了全面的文献搜索.
- 包括52项涉及93,286名患者的研究,以分析脂质水平与HF死亡率之间的关联.
- 随机效应模型和QUIPS工具用于统计分析和偏差风险评估.
主要成果:
- 无变量分析显示,高水平的TC,HDL-C,LDL-C和甘油三与HF患者的死亡率降低有关.
- 多变量分析证实,较低的TC和LDL-C水平独立与降低的死亡率有关.
- 危险比率表明,较高的脂质水平对各种参数的死亡率具有保护作用.
结论:
- 脂质参数水平升高与心力衰竭患者死亡率降低有关.
- 脂质配置文件可以作为有价值的辅助,以改善HF患者预测模型中的预后.
- 包含的研究的观察性质排除了关于因果关系的最终结论.
相关概念视频
01:30Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
01:30Heart Failure VII: Nursing Interventions
149
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
149
01:17Pathophysiology of Heart Failure
1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
229
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
229
01:26Atherosclerosis III: Management
44
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
44
01:22Heart Failure VI: Adjunct Therapies
40
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
40